07.03.2011 • News

South Korean Honam Considering Indonesia Petrochemical Plants

South Korea's Honam Petrochemical Corp said it was considering building a petrochemical complex in Indonesia, which market estimates indicate could cost up to 5 trillion won ($4.49 billion).

Asia's No.2 petrochemical maker reported to the stock market that it was considering building petrochemical plants in foreign countries including Indonesia under its mid- and long-term plans, although nothing had been finalized.

Honam has a combined production capacity of 2.5 million tons per year (tpy) in South Korea and Malaysia, where it received takeover approval from shareholders of Malaysia's largest petrochemicals maker Titan Chemicals Corp last December.

"This long-term investment consideration includes building an at least 1 million tpy naphtha cracker and downstream plants," said a company source, who declined to be identified because of the sensitivity of the issue. The source quoted a market estimate putting the cost of construction at up to 5 trillion won.

He said through 2015 the company would first sort out financing issues for the project to enable a final decision, while construction would take about a year to complete.

The completed complex would make Honam Petrochemical Asia's No.1 petrochemicals maker, he said, adding that this investment consideration was based upon studies of market outlook, and supply and demand balances.

Last month, South Korea's Lotte Group, which owns 57.2% of Honam Petrochemical, said it was considering investing as much as $5 billion to build a petrochemical plant in Indonesia.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.